Early clinical markers of aggressive multiple sclerosis

Author:

Malpas Charles B12,Manouchehrinia Ali3ORCID,Sharmin Sifat12,Roos Izanne12,Horakova Dana4,Havrdova Eva Kubala4,Trojano Maria5,Izquierdo Guillermo6,Eichau Sara6,Bergamaschi Roberto7,Sola Patrizia8,Ferraro Diana89,Lugaresi Alessandra1011,Prat Alexandre12,Girard Marc12,Duquette Pierre12,Grammond Pierre13,Grand’Maison Francois14,Ozakbas Serkan15,Van Pesch Vincent1617,Granella Franco18,Hupperts Raymond19,Pucci Eugenio20,Boz Cavit21,Sidhom Youssef22,Gouider Riadh23,Spitaleri Daniele24,Soysal Aysun25,Petersen Thor26,Verheul Freek27,Karabudak Rana28,Turkoglu Recai29,Ramo-Tello Cristina30,Terzi Murat31,Cristiano Edgardo32,Slee Mark33,McCombe Pamela3435,Macdonell Richard36,Fragoso Yara37,Olascoaga Javier38,Altintas Ayse39,Olsson Tomas40,Butzkueven Helmut414243,Hillert Jan40,Kalincik Tomas12ORCID

Affiliation:

1. CORe Unit, Department of Medicine, University of Melbourne, Melbourne, Australia

2. Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia

3. Centre for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden

4. Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic

5. Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari, Bari, Italy

6. Hospital Universitario Virgen Macarena, Sevilla, Spain

7. IRCCS Mondino Foundation, Pavia, Italy

8. Department of Neuroscience, Azienda Ospedaliera Universitaria, Modena, Italy

9. Department of Biomedical, Metabolic and Neurosciences, University of Modena and Reggio Emilia, Modena, Italy

10. Department of Biomedical and Neuromotor Science, University of Bologna, Bologna, Italy

11. IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy

12. CHUM and Universite de Montreal, Montreal, Canada

13. CISSS de Chaudière-Appalaches, Levis, Canada

14. Neuro Rive-Sud, Quebec, Canada

15. Dokuz Eylul University, Konak/Izmir, Turkey

16. Cliniques Universitaires Saint-Luc, Brussels, Belgium

17. Université Catholique de Louvain, Brussels, Belgium

18. Department of Medicine and Surgery, University of Parma, Parma, Italy

19. Zuyderland Ziekenhuis, Sittard, The Netherlands

20. UOC Neurologia, Azienda Sanitaria Unica Regionale Marche - AV3, Macerata, Italy

21. KTU Medical Faculty Farabi Hospital, Trabzon, Turkey

22. Department of Neurology, Razi Hospital, Manouba, Tunisia

23. Department of Neurology, Razi Hospital, LR 18SP03, Clinical Investigation Center Neurosciences and Mental Health, Faculty of Medicine University Tunis El Manar, Tunis, Tunisia

24. Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino, Avellino, Italy

25. Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases, Istanbul, Turkey

26. Kommunehospitalet, Arhus C, Denmark

27. Groene Hart Ziekenhuis, Gouda, The Netherlands

28. Hacettepe University, Ankara, Turkey

29. Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey

30. Hospital Germans Trias i Pujol, Badalona, Spain

31. Medical Faculty, 19 Mayis University, Samsun, Turkey

32. Hospital Italiano, Buenos Aires, Argentina

33. Flinders University, Adelaide, Australia

34. University of Queensland, Brisbane, Australia

35. Royal Brisbane and Women’s Hospital, Brisbane, Australia

36. Austin Health, Melbourne, Australia

37. Universidade Metropolitana de Santos, Santos, Brazil

38. Instituto de Investigación Sanitaria Biodonostia, Hospital Universitario Donostia, San Sebastián, Spain

39. Koc University, School of Medicine, Department of Neurology, Istanbul, Turkey

40. Department of Clinical Neuroscience, Karolinska Institutet, Sweden

41. Central Clinical School, Monash University, Melbourne, Australia

42. Department of Neurology, The Alfred Hospital, Melbourne, Australia

43. Department of Neurology, Box Hill Hospital, Monash University, Melbourne, Australia

Abstract

Abstract Patients with the ‘aggressive’ form of multiple sclerosis accrue disability at an accelerated rate, typically reaching Expanded Disability Status Score (EDSS) ≥ 6 within 10 years of symptom onset. Several clinicodemographic factors have been associated with aggressive multiple sclerosis, but less research has focused on clinical markers that are present in the first year of disease. The development of early predictive models of aggressive multiple sclerosis is essential to optimize treatment in this multiple sclerosis subtype. We evaluated whether patients who will develop aggressive multiple sclerosis can be identified based on early clinical markers. We then replicated this analysis in an independent cohort. Patient data were obtained from the MSBase observational study. Inclusion criteria were (i) first recorded disability score (EDSS) within 12 months of symptom onset; (ii) at least two recorded EDSS scores; and (iii) at least 10 years of observation time, based on time of last recorded EDSS score. Patients were classified as having ‘aggressive multiple sclerosis’ if all of the following criteria were met: (i) EDSS ≥ 6 reached within 10 years of symptom onset; (ii) EDSS ≥ 6 confirmed and sustained over ≥6 months; and (iii) EDSS ≥ 6 sustained until the end of follow-up. Clinical predictors included patient variables (sex, age at onset, baseline EDSS, disease duration at first visit) and recorded relapses in the first 12 months since disease onset (count, pyramidal signs, bowel-bladder symptoms, cerebellar signs, incomplete relapse recovery, steroid administration, hospitalization). Predictors were evaluated using Bayesian model averaging. Independent validation was performed using data from the Swedish Multiple Sclerosis Registry. Of the 2403 patients identified, 145 were classified as having aggressive multiple sclerosis (6%). Bayesian model averaging identified three statistical predictors: age > 35 at symptom onset, EDSS ≥ 3 in the first year, and the presence of pyramidal signs in the first year. This model significantly predicted aggressive multiple sclerosis [area under the curve (AUC) = 0.80, 95% confidence intervals (CIs): 0.75, 0.84, positive predictive value = 0.15, negative predictive value = 0.98]. The presence of all three signs was strongly predictive, with 32% of such patients meeting aggressive disease criteria. The absence of all three signs was associated with a 1.4% risk. Of the 556 eligible patients in the Swedish Multiple Sclerosis Registry cohort, 34 (6%) met criteria for aggressive multiple sclerosis. The combination of all three signs was also predictive in this cohort (AUC = 0.75, 95% CIs: 0.66, 0.84, positive predictive value = 0.15, negative predictive value = 0.97). Taken together, these findings suggest that older age at symptom onset, greater disability during the first year, and pyramidal signs in the first year are early indicators of aggressive multiple sclerosis.

Funder

National Health and Medical Research Council of Australia

MSBase Foundation

Novartis

Charles University in Prague

Czech Minsitry of Education

Czech Ministry of Health

Czech Ministry of Education

Fondazione Italiana Sclerosi Multipla

Publisher

Oxford University Press (OUP)

Subject

Neurology (clinical)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3